Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional GenomicsJanuary 21, 2022
January 21, 2022, Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a Global Master Services Agreement with My Next Health (“MNH”), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.
My Next Health Inc. (“MNH”) is the world’s leading patient-based AI-functional genomic medical analysis company. MNH is improving human health and accelerating the world’s transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual’s health recommendations and clinical trial outcomes. MNH algorithms significantly impact clinical trial subject selection.
Hemostemix will incorporate MNH’s functional genomic assays to complete an assay report by individual. Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double blind placebo controlled clinical trial.
“We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine,” stated Dr. Richard Heinzl, CEO, MNH.
“MNH’s tools and analyses enables Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly de-risks our clinical trials going forward,” stated Thomas Smeenk, CEO.
ABOUT MY NEXT HEALTH
My Next Health Inc. (“MNH”) is the world’s leading patient focused, AI-functional-medicine-based genomic medical analysis company. MNH is improving human health and accelerating the world’s transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual’s health recommendations and clinical trial outcomes. MNH algorithms will significantly impact clinical trial subject selection.
Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy and Dilated Cardiomyopathy. ACP-01 has been used to treat over 300 patients. ACP-01 is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com.
For further information, please contact:
Contact: Thomas Smeenk, President, CEO & Co-Founder
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the use of AI based genomic assays that may impact the commercialization of ACP-01, with or in combination with other analytics. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the “Litigation”); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies as well as management’s expectations of anticipated results; Hemostemix’s general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix’s operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory analyses and the results of such analyses and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View All News & Media